Vantage logo

Big caps provide a safe haven

As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.

Vantage logo

Pharma news over the Christmas period

If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.

Vantage logo

Keytruda wins 2018’s biggest sales upgrade

Vantage takes a look at the sellside’s naughty and nice list for 2018: prospects improved considerably for Merck & Co’s Keytruda and Abbvie’s Mavyret, the latter…

Vantage logo

Idera’s reinvention takes a hit

The company’s lead, tilsotolimod, is meant to turn cold tumours hot, but it was investors who became frosty last week in response to mid-stage clinical results.